GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Bitter Melon Component and Colon Cancer Prevention

$544,710
Shrikant Anant · University Of Kansas Medical Center · R01 · FY2017 · CA

Bitter Melon Component and Colon Cancer Prevention

$544,710
Shrikant Anant · University Of Kansas Medical Center · R01 · FY2016 · CA

Training Program in Basic Cancer Research

$544,673
Maureen E Murphy · Wistar Institute · T32 · FY2019 · CA

Defining metabolic adaptations within the PDAC "arid" tumor microenvironment

$544,659
Chi V. Dang · Johns Hopkins University · R01 · FY2023 · CA

Functional Relevance of Pyrimidine Sensing and Response Pathways in Tumor Metabolism and Cancer Therapy

$544,658
Richard Lewis Possemato · New York University School Of Medicine · R01 · FY2024 · CA

Functional Relevance of Pyrimidine Sensing and Response Pathways in Tumor Metabolism and Cancer Therapy

$544,658
Richard Lewis Possemato · New York University School Of Medicine · R01 · FY2025 · CA

MRI Radiomic Signatures of DCIS to Optimize Treatment

$544,651
Habibollah Rahbar · University Of Washington · R01 · FY2024 · CA

Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction

$544,635
Amy E Moran · Oregon Health & Science University · R37 · FY2022 · CA

Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction

$544,635
Amy E Moran · Oregon Health & Science University · R37 · FY2025 · CA

Project 2

$544,481
Paolo Provenzano · University Of Minnesota · P01 · FY2022 · CA

Project 2

$544,481
Paolo Provenzano · University Of Minnesota · P01 · FY2023 · CA

Decoding the metabolic routes of purine nucleotides in cancer - Resubmission - 1

$544,478
Gerta N/a Hoxhaj · Ut Southwestern Medical Center · R01 · FY2025 · CA

Tissue engineered organ-specific cancer metastasis model for cancer research

$544,475
Andrew Zhuang Wang · Ut Southwestern Medical Center · R01 · FY2025 · CA

Tissue engineered organ-specific cancer metastasis model for cancer research

$544,475
Andrew Zhuang Wang · Ut Southwestern Medical Center · R01 · FY2024 · CA

Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer

$544,425
Xiaoguang Margaret Liu · Ohio State University · R01 · FY2024 · CA

Influences of the Microenvironment on Cancer Stem Cells

$544,406
Hong Wu · University Of California Los Angeles · U01 · FY2013 · CA

Artificial, Humanized Stem Cell Niches

$544,399
Biju Parekkadan · Rutgers, The State Univ Of N.J. · R01 · FY2019 · EB

ANALYSIS OF INTRAHEPATIC MACROPHAGE PROFILES FOR PREDICTING RISK OF FIBROSIS DEVELOPMENT IN PATIENTS WITH DIFFERENT TYPES OF CHRONIC LIVER DISEASE

$544,399
Heather L Stevenson · University Of Texas Med Br Galveston · R01 · FY2021 · DK

Sideport Needle Array Technologies for Prioritizing Drugs for Cancer Patients

$544,375
James M Olson · Presage Biosciences, Inc. · R42 · FY2011 · CA

CLINICAL THERAPY TRIALS

$544,224
Katherine Kurshan Matthay · Children'S Hospital Of Los Angeles · P01 · FY2007 · CA

Targeting MTOR signaling in pancreatic cancer

$544,134
Brian C Lewis · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · CA

Map Leukemia-immune Cell Talks with Nanoplasmon Ruler in CAR T-Cell Immunotherapy

$544,131
Weiqiang Chen · New York University · R01 · FY2020 · CA

MRI and blood biomarkers of neoadjuvant therapy response and outcomes in rectal cancer

$544,093
Ruijiang Li · Stanford University · R01 · FY2025 · CA

A Portable low-cost, Point of Investigation CapCell Scope to Image and Quantify the Major Axes of Metabolism and the Associated Vasculature in In vitro and In vivo Biological Models

$544,076
Nimmi Ramanujam · Duke University · R01 · FY2019 · EB

The Role of HIF2 in Pancreatic Ductal Adenocarcinoma

$544,035
Albert Koong · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA